Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 4/20 | 0.57 |
| ▸ | PPARA | Q07869 | 4/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262556 | 0.86 | CYP1A2 (0.77) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL4650970 | 0.85 | CYP1A2 (0.61) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL14533739 | 0.85 | CYP1A2 (0.61) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL1811398 | 0.84 | CYP1A2 (0.59) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL10207277 | 0.84 | CYP2C9 (0.59) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL11539024 | 0.84 | CYP1A2 (0.59) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL6449049 | 0.84 | CYP1A2 (0.59) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL1125165 | 0.84 | CYP1A2 (0.59) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL13557308 | 0.82 | CYP1A2 (0.57) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL17710847 | 0.82 | CYP1A2 (0.67) | CYP1A2GAACYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119451974-A | Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens | 巴塞罗那全球健康研究所私人基金会 | 2025-02-14 | — | — | CN | disclosed |
| EP-3986914-A1 | CONSTRAINED PEPTIDES | TearSolutions, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20120245213-A1 | HUMAN TYPE I TASTE RECEPTOR SUBUNIT 3 MODULATORS AND METHODS OF USING SAME | MOUNT SINAI SCHOOL OF MEDICINE | 2012-09-27 | — | — | US | disclosed |
| WO-2001027077-A2 | HYDROXYSULFONYLALKYLENE-, PHOSPHONOALKYLENE- OR DIFLUORO(PHOSPHONONON)METHYL- SUBSTITUTED BENZENE, OR BENZOFURAN DERIVATIVES AS NON-PEPTIDIC CDC25 INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-19 | — | — | WO | disclosed |
| US-5180730-A | Pyridylthiomethyl-Substituted Phenols, Antianaphylactic Agents | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1993-01-19 | — | — | US | disclosed |
| US-4933348-A | MEDICINES; ANTAGONISTS OF SLOW REACTING SUBSTANCE OF ANAPHYLAXIS; PROPHYLAXIS AND TREATMENT OF ALLERGIC DISEASES | MASE TOSHIYASU (JP) | 1990-06-12 | — | — | US | disclosed |
| US-4803211-A | Thiadizazole compounds as antagonists of SRS-A | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1989-02-07 | — | — | US | disclosed |
| EP-0214732-A2 | (Substituted benzyl)-thio heterocyclic compounds having a leukotriene-antagonist activity | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1987-03-18 | — | — | EP | disclosed |
| US-4039683-A | PHENOXYPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-08-02 | — | — | US | disclosed |
| US-3968143-A | Phenoxypropionic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245213-A1 | HUMAN TYPE I TASTE RECEPTOR SUBUNIT 3 MODULATORS AND METHODS OF USING SAME | TAS1R3, TAS2R3, TAS1R1 | CYP1A2 4546/4885GAA 628/4885CYP2C9 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.